Cargando…

High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer

INTRODUCTION: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer with poor prognosis and resistance to hormone therapy, which has limited therapeutic approaches. Therefore, this study aimed to identify a novel treatment for NEPC and provide evidence of its inhibitory e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lei, Ji, Yiyi, Li, Ang, Liu, Bo, Shen, Kai, Su, Ruopeng, Ma, Zehua, Zhang, Weiwei, Wang, Qi, Zhu, Yinjie, Xue, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042075/ https://www.ncbi.nlm.nih.gov/pubmed/36994207 http://dx.doi.org/10.3389/fonc.2023.1085569

Ejemplares similares

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation
por: Su, Ruopeng, et al.
Publicado: (2022)

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer
por: Ji, Yiyi, et al.
Publicado: (2023)

Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer
por: Chung, Ivy, et al.
Publicado: (2021)

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Ma, Zehua, et al.
Publicado: (2022)

Screening to Identify an Immune Landscape-Based Prognostic Predictor and Therapeutic Target for Prostate Cancer
por: Shen, Yanting, et al.
Publicado: (2021)

A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers
por: Elhasasna, Hussain, et al.
Publicado: (2022)

The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression
por: Terry, Stéphane, et al.
Publicado: (2014)

Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2015)

Primary neuroendocrine prostate cancer with adrenal gland metastasis
por: Muñoz López, Antonio Yaromin, et al.
Publicado: (2021)

High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer
por: Ku, Anson, et al.
Publicado: (2021)

Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine?
por: Grigore, Alexandru Dan, et al.
Publicado: (2015)

A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
por: Zhang, Shanshan, et al.
Publicado: (2019)

The Evolving Role of (18)F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer
por: Shen, Kai, et al.
Publicado: (2021)

Neuroendocrine Differentiation in Prostate Cancer: A Mechanism of Radioresistance and Treatment Failure
por: Hu, Chang-Deng, et al.
Publicado: (2015)

Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression
por: Wang, Zheng, et al.
Publicado: (2020)

A rare case of prostate neuroendocrine tumor: A case report
por: Teh, Shunxing, et al.
Publicado: (2022)

Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction
por: Lao, Yueqiong, et al.
Publicado: (2022)

Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report
por: Hara, Midori, et al.
Publicado: (2022)

Co-occurrence of Dermatomyositis and Polycythemia Unveiling Rare de Novo Neuroendocrine Prostate Tumor
por: Papagoras, Charalampos, et al.
Publicado: (2018)

Hypercalcemia due to parathyroid hormone-related peptide secreted by neuroendocrine dedifferentiated prostate cancer
por: Ando, Takashi, et al.
Publicado: (2018)

Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases
por: Zhang, Qingfu, et al.
Publicado: (2021)

A bibliometric study of the top 100 most-cited papers in neuroendocrine prostate cancer
por: Gan, Yu, et al.
Publicado: (2023)

FLUOXETINE IN TRICHOTILLOMANIA - A THERAPEUTIC DILEMMA
por: Bhatia, M.S., et al.
Publicado: (1993)

Gross Findings of Widespread Visceral Metastasis of Prostatic Adenocarcinoma With Neuroendocrine Features: A Case Report
por: Habibian, David J., et al.
Publicado: (2016)

Pancreatic metastasis from locally recurrent neuroendocrine differentiated prostate cancer after radical prostatectomy
por: Ando, Takashi, et al.
Publicado: (2020)

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase
por: Hakozaki, Yuji, et al.
Publicado: (2018)

Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer
por: Nichols, Anthony C, et al.
Publicado: (2014)

Androgen-Targeted Therapy-Induced Epithelial Mesenchymal Plasticity and Neuroendocrine Transdifferentiation in Prostate Cancer: An Opportunity for Intervention
por: Nouri, Mannan, et al.
Publicado: (2014)

Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network
por: Lee, Ahn R., et al.
Publicado: (2018)

Investigation of Neural Microenvironment in Prostate Cancer in Context of Neural Density, Perineural Invasion, and Neuroendocrine Profile of Tumors
por: Sigorski, Dawid, et al.
Publicado: (2021)

JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
por: Pawar, Jogendra Singh, et al.
Publicado: (2023)

Molecular Screening for Nigericin Treatment in Pancreatic Cancer by High-Throughput RNA Sequencing
por: Xu, Zhihua, et al.
Publicado: (2020)

Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy
por: Alkhilaiwi, Faris
Publicado: (2021)

Comprehensive Analysis of Cell Cycle-Related Genes in Patients With Prostate Cancer
por: Liu, Zehua, et al.
Publicado: (2022)

Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers
por: Soundararajan, Rama, et al.
Publicado: (2018)

Differential Gene Expression and Weighted Correlation Network Dynamics in High-Throughput Datasets of Prostate Cancer
por: Mohammad, Taj, et al.
Publicado: (2022)

Whole exome sequencing identifies common mutational landscape of cervix and endometrium small cell neuroendocrine carcinoma
por: Wang, Wei, et al.
Publicado: (2023)

Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration
por: Aristieta, A., et al.
Publicado: (2013)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
por: Bergamini, Marco, et al.
Publicado: (2022)

Near-Infrared Fluorescent Agent for In Vitro Screening of Endometrial Cancer and Precancerous Lesions
por: Liang, Dongxin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2btck5o52hcp818hjaefml36op